Thirona is present during the congress of the American Thoracic Society from May 14-19. Due to the COVID-19 pandemic the congress is held online but you can come by our booth and get more information about our products, such as CAD4COVID and LungQ. You can join and register via this link. We will also present about our research on new biomarkers in COPD and on IPF. Our abstracts are summarised below, but please visit our booth for more information.

We are also present at the Dutch Radiologiedagen which are also held online on 20 and 21 May. If you want to register and see the program please visit this link.

We have made a video to show what we do:



Abstract 1: The role of the pulmonary vasculature in COPD is not well understood. Thirona’s LungQ software makes it possible to automatically quantify pulmonary arteries and veins from chest CT scans, and we have found that the mean diameter of the central arteries (MCA) is a good biomarker for airflow obstruction in patients that suffer from COPD. An increase of MCA was independently associated with worse spirometry and quality of life, even when adjusted for the extent of emphysema.

Abstract 2: Peripheral airways disease play an important role in the pathophysiology of COPD. Thirona’s LungQ software automatically quantifies central and peripheral airway-artery dimensions on chest CT scans, which have shown to contribute to airflow obstruction in patients suffering from COPD. Airway-artery dimensions are quantified by matching airways to their adjacent arteries to obtain the airway-artery ratio for both central and peripheral airway. We showed that these peripheral and central airway measurements, in addition to emphysema, contribute significantly to spirometric indicators of airflow obstruction.

Abstract 3: Idiopathic Pulmonary Fibrosis (IPF) is a progressive and fatal condition with a variable disease course. We have developed algorithms to automatically quantify the airway wall thickness and arterial caliper from thoracic CT in patients suffering from IPF. These biomarkers have shown, in addition to the extent of pulmonary fibrosis, to help stratify disease severity, evaluate progression, and may provide prognostic information in patients with IPF.